Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
National Institutes of Health
Award ceiling
—Award floor
—Posted
Dec 2, 2024Closes
Nov 16, 2027Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Health, Income Security and Social Services
Eligible applicants: Native American tribal governments (Federally recognized), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, City or township governments, Others (see text field entitled "Additional Information on Eligibility" for clarification), Native American tribal organizations (other than Federally recognized tribal governments), Public and State controlled institutions of higher education, County governments, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, For profit organizations other than small businesses, Special district governments, Public housing authorities/Indian housing authorities, State governments, Independent school districts, Small businesses
Description
This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.